← Search & browse all drugs

colfosceril palmitate

R07AA01

Forms & Strengths

Intratracheal suspension: 108 mg/vial colfosceril palmitate (synthetic surfactant, component of Exosurf Neonatal)
Reconstitution diluent: 8 mL sterile water for injection

Adult Dosing

Not applicable (indicated exclusively for neonatal populations)

Pediatric Dosing

Prophylaxis in premature infants at risk for respiratory distress syndrome (RDS): 5 mL/kg intratracheally as soon as possible after birth (ideally within 24 hours), followed by repeat doses at 12 and 24 hours if RDS develops
Rescue treatment in infants with established RDS: 5 mL/kg intratracheally as soon as possible after diagnosis, with a repeat dose 12 hours later if RDS persists

Indications

Prevention and treatment of respiratory distress syndrome (RDS) in premature infants

Mechanism of Action

Synthetic pulmonary surfactant containing dipalmitoylphosphatidylcholine (DPPC), cetyl alcohol, and tyloxapol
Lowers surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse at end-expiration and reducing the work of breathing

Contraindications

No specific absolute contraindications known in the setting of emergency neonatal RDS treatment when administered under experienced supervision

Adverse Reactions

Transient bradycardia
Oxygen desaturation
Endotracheal tube blockage
Pulmonary hemorrhage
Apnea
Mucus plugging

Drug Interactions

No formal drug-drug interaction studies performed in neonates
Concomitant medications typically include routine neonatal intensive care therapies (e.g., caffeine, parenteral nutrition, antibiotics); monitor closely for cardiorespiratory instability during administration

Curated Content: Needs Vetting Before Put to Clinical Use